Implications for human health. by Golberg, L
Environmental Health Perspectives
Vol. 32, pp. 273-277, 1979
Implications for Human Health
by Leon Golberg*
To analyze the implications for human health, the toxicologist requires four sets ofdata: the results of
toxicity and other studies in animals; quantitative data on actual or potential human exposure; whatever
information is available on effects of exposure in man; and the statistical extrapolations from the dose-
response relationships in animals to the (usuafly) much lower levels of human exposure. Professional
expertise in toxicolgy is essential to assess the nature andseverity ofthe toxiceffects observed in animals,
including such characteristics as potential for progression, irreversibility and production ofincapacity.
Given sufficient data, an estimate can be arrived at of the likelihood that such effects will he elicited in
huiman populations ofdiffering susceptibilties. The criteria by which the overall implications for human
healthcanbejudgedcompriseboththedirecteffectsonman, asweUlastheindirectconsequencesstemming
from environmental impacts.
Inaddressinganaudience attunedtotheemphases
in today's media campaigns, a certain amount of
'deprogramming' is necessary. All toxicity is not
cancer, norbirth defects. To the question: what else
is there? - the answer is: a virtually infinite variety
ofotherchanges. Onthe one hand, alarge numberof
organs and functions exist in the body that may be
adversely affected by toxic agents. On the other, the
environment ofwhich man forms a part is not, and
never was, a pnstine background of "organic"
existence generating zero incidence of adverse ef-
fects. That myth, so beloved by the romanticists, is
notareflection ofreality. Furthermore, blindfaith in
statistical significance, following its conclusions
whereverthey may lead, is aptto spawnfallacies, as
this audience well knows. One particularly heinous
fallacy is the inference of causality from statistical
association. Another is disregard of biological sig-
nificance, that is, biologically-informed insight into
the nature and causation oftoxic effects. "Eyeball-
ing" the data, and using perspective based on
knowledge and experience - especially of the his-
torical background of spontaneous pathological
changes in laboratory animals - can contribute
materially tointerpretation ofresults and to sophisti-
cated assessment of risk.
Throughout the course oftoxicological investiga-
tions, the objective is to develop dose-response re-
lationships for observed toxic effects and to en-
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deavorto define the highest dose that does not elicit
manifestations of toxicity in susceptible hosts. On
the basis of this information, an appraisal of the
implications for human health, that is, a risk assess-
ment, is attempted. The process by which this con-
clusionisreachedis summedupinClaude Bernard's
equivalent of the classical "I came, I saw, I con-
quered": an observation is made; a comparison is
established; and a judgment is rendered. For the
purpose of this presentation, we start with the as-
sumption that an observation has been made in labo-
ratory animals, and consider the basis upon which
the scientist, as befits his or herprofessional respon-
sibility, ultimately arrives at an estimate of risk to
human health.
Establishing a Comparison
Some criteriaofthe validity ofanimal datafor use
in human risk assessment are presented in Table 1.
For any experiment, the report itselfprovides inter-
nal evidence ofthe quality ofworkperformed and of
the individuals involved. With the advent of regu-
lations defining good laboratory practice, consider-
able improvements in the conduct of laboratory
studiesmaybeanticipated. Nevertheless, suchisthe
variety and complexity of toxicological investiga-
tions that prescribed procedures can cover only
those aspects that are necessary for regulatory
agency and legal purposes.
Before attempting to establish a comparison, it is
advisable to ascertain the meaningfulness ofthe test
October 1979 273Table 1. Validity of animal data.
Quality of laboratory: Personnel, facilities, animals, animal
care, records
Protocol: Design and execution (sample size,
dose, duration)
Pathologists: Input, grossand microscopic appraisals
Quality of data: Internal evidence
Dose-response characteristics
Consistency, reproducibility
Loose ends
or tests under consideration. One example is the
production ofteratain chick embryos by injection of
foreign materials into the hen's egg. Striking effects
may be elicited, even by grains of sand. It is ques-
tionable whether relevant conclusions concerning
mammalian reproductive effects can be drawn from
a closed system like the avian egg (1). Another test
that requires cautious interpretation involves re-
peated subcutaneous or intramuscular injection of
thetestcompound in high doses into rats ormice (2).
Irondextran complex, introduced into clinical medi-
cine in 1954, was later shown to produce a variety of
sarcomas in high yields under these conditions (3-5);
25 years and millions of patients later, not a single
human case of sarcoma or other form of neoplasia
has been shown to be clearly attributable to iron
dextran (6).
Such considerations are appropriate at this time,
inview ofthe widespread eagerness -amounting in
some instances to ill-advised haste - to adopt
newly-developed "short-term" tests (of mutagenic
potential) for regulatory purposes. Until such tests
areadequatelyvalidated, theirsuitability, reliability,
reproducibility, precision, sensitivity, and specific-
ityareopentoquestion (7). Thecurrentinternational
effort at validation, after more than two years of
intensive work, has served to demonstrate the dif-
ficulties that still exist in standardizing the proce-
dures used in eventhe most(superficially) "simple"
short-term tests (8).
The assessment of severity ofa toxic effect often
goes beyond readily-quantifiable measurements
(Table 2). The general characteristics ofthe changes
elicited should be taken into consideration; beyond
those, the nature of the target tissue is a critical
factor. Inthe absence ofhuman datato indicate with
some certainty the likely human target organ, one
has at least to question whether the animal findings
arelikelytobeapplicable to man. Astrikingexample
of a structure that does not exist in man is the
tapetumlucidum ornictitating membrane inthe eyes
of dogs and cats. The ocular toxocity of hydroxy-
pyridinethione and zinc pyridinethione, which pro-
duceblindness indogs, isattributable to anactionon
the tapetum. Atapetal dogs and rhesus monkeys
suffer no ill effect (9). The drug ethambutol, among
other zinc-chelating compounds, is a similar case in
point(10-13). Inneithercase isthere any evidence of
an ocular effect in man.
The manifestations of systemic toxicity that need
to be taken into account in assessing severity are
indicated in Table 2. The nature and extent ofdam-
age brought about, and the particulartissue in which
itoccurs, are key considerations. Adiscussion along
these lines has been published (14), in which the
issues of regeneration, repair and restoration of
function are categorized for various tissues: those
having little or no capacity for regeneration (repair
throughfibrous replacement, as in nerve and muscle
cells, including myocardium); those whose cells do
not normally replicate but retain the ability to do so
inresponse to damage (liver, kidney, type 2 alveolar
epithelium); and labile tissues that continually pro-
liferateandreplacethemselves(surfaceepitheliaand
hemopoietic tissue). Cumulative, progressive and ir-
reversible effects should be weighed, particularly in
the first of these tissue categories. The issue of ir-
reversibility, however, calls for caution, since there
is increasing evidence of the apparent reversibility
(on discontinuation of exposure) of early changes
brought about by carcinogens, for example, in blad-
der epithelium and liver (15, 16).
A Judgment is Rendered
The relevance of animal data for human risk as-
sessment is based on a variety ofconsiderations set
out in Table 3. Some aspects have been discussed
above. Of the remainder, metabolism and phar-
macokinetics are of major importance. A detailed
discussion of this area of toxicology has been pub-
lished recently (17). In attempting to render ajudg-
ment on human risk, the question of "saturation
Table 2. Criteria of severity of toxic effect.
General characteristics
Acute: Reversible or irreversible
Chronic: Progressive, cumulative, reversible or
irreversible
Mutagenesis, carcinogenesis
Reproduction, development, teratogenesis
Immunologic effects
Behavioral changes
Nature of target tissue
Reserves offunction
Capacity for regeneration, repair, restoration of function
Nature and extent of damage
Changes in organ function (and other tests)
Liver, kidney, bone-marrow
Special function tests
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Limnitations of animal data
Species and strain differences
Genetic uniformity
Diet, controlled environment
Gnotobiotic state
Specificity of toxic action(s)
Interspecies differences
Relevance of affected organ
Metabolism and pharmacokinetics
Interspecies comparisons (including humans)
Dose relationshipstoriietaboliccharacteristics andimpacton
defense mechanisms
Parallelism of covalent binding and toxicity.
point" is vital. This refers to the level ofexposure in
a saturable, dose-dependent metabolic process at
which the capacity of the body's defensive mecha-
nisms is exceeded. In consequence, the linear, first-
order kinetics change to zero-order kinetics (18-21).
Unfortunately, little is known quantitatively about
the human body's response with regard to capacity
tomaintain defensive levels ofglutathione and other
nonprotein sulfhydryl compounds in various organs
in the face of mounting exposure to toxicants, or
their chemically reactive metabolites, that require
detoxification by a route involving thiol derivatives.
Equally, the methods developed for detection and
measurement of covalent binding of chemically
reactive metabolites to cellular protein, phos-
pholipid, DNA, and RNA are not readily applicable
tononinvasive human studies. Osterman-Golkarand
her colleagues (22) and Truong, Ward, and Legator
(23) have made efforts in this direction, but much
remains to be done. That a high priority should be
allotted to such work is evidenced by observations
on the parallelism between the amount of vinyl
chloride metabolized or the extent ofcovalent bind-
ing of labeled vinyl chloride metabolites to liver
protein, and the incidence of angiosarcoma of the
liver in rats (19).
Analysis of the implications for human health
(Table 4) should take into account differences in
human susceptibility (Table 5), which are based
partly on ability to adapt to exposure, metabolic
capacity, detoxication potential and reserves of
function. Assessment of the extent of exposure of
the population is often difficult, and calls for arbi-
trary decisions. Where exposure is partly orentirely
through food, the so-called "glutton syndrome' en-
ters into the picture and allowance should be made
for the 90th percentile of consumption.
The need for information on human exposure to a
compound and its effects is self-evident; but the
quest for such data is often difficult and calls for
determination and dogged persistence. Of the cate-
Table 4. Analysis of inplications for human health.
1. Results of toxicity and other studies in animals
2. Quantitative data on actual or potential human exposure
3. Data on human health effects
4. Statistical extrapolations from dose-response relationships to
levels ofhuman exposure
gories of human information that may be available
(17, 24), the results of human exposure under con-
trolled conditions are particularly valuable. For the
most part, however, epidemiological studies are the
source of human information usually relied upon.
Unfortunately, the bias of the cancer enthusiasts is
such that positive results ofepidemiological studies
are emphasized but negative findings are subjected
to nitpicking which, ipso facto, renders them "con-
troversial" and hence capable ofbeing safely disre-
garded. Conversely, case reports orepidemiological
associations, however tenuous, suffice to label a
compound as a human carcinogen, irrespective of
the number and high quality of negative long-term
studies in animals (25).
An instructive example ofpositive findings in ani-
mal carcinogenesis bioassays is that ofphenobarbi-
tal, which has yielded hepatic adenomas and car-
cinomas in mice and limited evidence ofbenign liver
tumors in rats (26-30). By today's standards,
phenobarbital would not be accepted for use as a
drug. Happily, half a century of experience of its
value and safety in the treatment of epilepsy has
afforded an opportunity for a well-conducted
epidemiological studycarriedoutbyClemmesenand
Hjalgrim-Jensen(31), whofollowedupatotalof9136
epileptic patients admitted to the epileptic colony at
Filadelfia, in Denmark, over the period 1933-1962.
Up to December 1972, after making allowance for
patients in whom thorotrast had been used for an-
giography, three casesoflivercancerwerefound, as
against 2.1 cases expected. The excess of brain
tumors was just that to be anticipated in epileptic
individuals. It is worth quoting Clemmesen's cri de
coeur (31)
". . . ifthe evidence presented here for 8,078 persons fol-
lowed for one or two decades should carry no weight in the
discussion on the postulated carcinogenicity ofphenobarbital
we may as well abandon cancer epidemiology."
Is phenobarbital acting as a modifying factor for
Table 5. Differences in host susceptibility.
Genetic factors
Constitutional factors
Dietary factors
Life style: alcohol, tobacco, exercise, drugs
Occupational exposures
Environmental exposures
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cancer viruses, that are present in mice? This possi-
bility, linked to the fact that Clemmesen's studies
were carried out in human adults, and that brain
tumors in children may differ etiologically from
those in adults, led Gold and her colleagues (32) to
study the risk ofbrain tumors in children exposed to
barbiturates. Theirresults suggested thatupto8% of
brain tumors in children may be attributable to in-
gestion of barbiturates by the children themselves
or, prenatally, by their mothers.
An important step in hazard analysis is the com-
parison ofthe risk under consideration with the gen-
eral background of risk to man from "natural"
foods, air and water, just as low-level radiation
hazards arejudgedagainstthe natural background of
cosmic and other radiation. Strangely enough, no
attempt has evern been made to assess background
chemical risk from the natural environment, to
which man has presumably been exposed from time
immemorial. Yet, estimates of this kind are vitally
necessary in risk assessment, even for products of
combustion entering the atmosphere. From the food
additive area comes a current illustration. Nitrite
used as an additive inthe preparation ofcured meats
seems likely to be banned inthe nearfuture. Yet, the
nitrite in cured meat constitutes at most 2-3% ofthe
total nitrite to which the body is exposed; 82% is
formed directly in the human intestine (33), and 15%
enters through the saliva as a result ofconversion of
dietary nitrate to nitrite by microorganisms in the
buccal cavity. What benefit to anyone is likely to
flowfrom regulatory action toeliminate, on average,
1% of nitrite exposure? On the basis of measure-
ments of volatile nitrosamines in human blood and
feces, the calculated daily human exposure to di-
methylnitrosamine is in the range 500-5000 ,ug; meat
products contribute 0.5 ,ug and 30 cigarettes 0.6 ,ug
(34). As far as we can tell, most ofthe rest of these
carcinogens are synthesized within the body (35).
What lessons flow from these examples? Hazard
analysis must considerthree components: potential,
the intrinsic ability of a compound to elicit toxic
effects, for instance, mutagenic/carcinogenic
changes; potency, which covers a range of at least
107; and opportunity, i.e., exposure, with a range of
at least 108. Since the two latterfactors are indepen-
dent ofeachother, the total potency associated with
exposure covers a dose range of 1015. What this
means is that there is aneed to discriminate between
compounds at the upper end ofthis enormous spec-
trum and those at the lower end. In taking appro-
priate precautions, the approach that would treat all
alike suffers from the disadvantage that many com-
pounds will be subject to excessive or even super-
fluous restrictionswhereasthe reallybad actors may
not be covered strictly enough.
In real life, the range of potency x exposure is
likely to exceed 1015 because of mitigating factors
(physiological and homeostatic mechanisms, in-
teractions, competition, detoxication) modulating
factors(effectsonmetabolism, DNArepair, immune
response) and modifying factors influencing
mutagenic, carcinogenic and otherresponses. Thus,
the total impact ofthe compound may be expressed
in terms of an unsolved equation (36), in which the
firsttermcontainsanunknowncoefficientmultiplied
by the biological activity of the compound, for in-
stance its carcinogenic potential. To this term must
be added others, representing the products of un-
known coefficients and the activities of (a) syncar-
cinogens, cocarcinogens, promoters and modifying
factors, (b) carcinogens present in "natural" foods
and (c) carcinogens formed endogenously by the
human body. Terms to be subtracted are the prod-
ucts of unknown coefficients and (a) the protective
actions ofbodily defense and adaptive mechanisms,
(b) the activities ofanticarcinogens and other tumor
suppressants present in and entering the human
body. While such asolution is probably a pipedream
at present, efforts in this direction will make for
better and better hazard evaluations.
Conclusion
To analyze the implications for human health, the
toxicologist requires four sets ofdata: the results of
toxicity and other studies in animals; quantitative
data on actual or potential human exposure; what-
ever information is available on effects of exposure
in man; and the statistical extrapolations from the
dose-response relationships in animals to the (usu-
ally) much lower levels ofhuman exposure. Profes-
sional expertise in toxicology is essential to assess
the nature and severity ofthe toxic effects observed
in animals, including such characteristics as poten-
tial for progession, irreversibility and production of
incapacity. Given sufficient data, an estimate can be
arrived at ofthe likelihood that such effects will be
elicited in human populations of differing suscep-
tibilities. The criteria by which the overall implica-
tions for human health can bejudged comprise both
the direct effects on man, as well as the indirect
consequences stemming from environmental im-
pacts.
This presentation has deliberately avoided such
controversial issues as that of thresholds for
mutagens/carcinogens, or the weaknesses of car-
cinogenesis bioassays in laboratory animals. In-
stead, emphasis has been placed on commonsense
Environmental Health Perspectives 276issues on which general agreement may be antici-
pated. One of these is the dictum that scientific
judgment should rest on the weight ofscientific evi-
dence; compound character assassination is not
good toxicology. Equally, the implications ofanimal
dataforhuman health can only be assessedby scien-
tists - not lawyers - on a solid scientific basis. A
physician can advise, but is not trained to interpret
toxicological data. A lawyer can do neither. In this
context, there is an important difference between
science and law in regard to the evidence needed for
attribution ofcausality to statistical association be-
tween postulated causes and observed effects.
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